Comprehensive intratumoral heterogeneity landscaping of liver hepatocellular carcinoma and discerning of APLP2 in cancer progression

被引:6
|
作者
Tao, Zhigang [1 ]
Huang, Jing [2 ]
Li, Jun [2 ]
机构
[1] Hangzhou Canc Hosp, Dept Radiol, Hangzhou, Zhejiang, Peoples R China
[2] Hangzhou Canc Hosp, Dept Integrated Oncol, Hangzhou, Zhejiang, Peoples R China
关键词
APLP2; disulfidoptosis; liver hepatocellular carcinoma; prognostic model; tumor heterogeneity; TOPOISOMERASE-II-ALPHA; BOX BINDING-PROTEIN; EXPRESSION; YB-1; RESISTANCE; APOPTOSIS; CELLS; P53;
D O I
10.1002/tox.23904
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
IntroductionAs the sixth most common type of cancer worldwide, liver hepatocellular carcinoma (LIHC) emerges as grave public health danger owing to its chemotherapy-resistant feature. Disulfidoptosis is a newly discovered programmed cell death process affecting the normal actin cytoskeleton structure. MethodsSingle-cell RNA (scRNA)-seq data were procured from GSE149614 and GSE202642 datasets. We utilized uniform manifold approximation and projection and clustering algorithm Louvian for dimensionality reduction and FindAllMarkers function for determining the differentially expressed genes (DEGs). Monocle2 and SCENIC were utilized to perform pseudo-time series and transcription factor analysis for selected subgroups. A series of in vitro experiments, including colony formation assay (CFA), flow cytometry targeting apoptosis and cell cycle, was applied to investigate how APLP2 regulated the LIHC progression. Two cell lines of LIHC cells, HepG2, and Huh7, were used for si-APLP2 transfection. ResultsTumor heterogeneity landscape of LIHC was depicted by detailed subgroup analysis. We found T and B cells were enriched with POU2F1 and HES1 activity. Inflammatory cancer-associated fibroblasts interacted with the cancer cells, uniquely through COL1A1/SDC1, COL1A2/SDC1 and LUM/ITGB1 pathways. The transformation from normal hepatocytes to malignant cells was displayed by cell trajectory analysis. State4, which was determined as malignant cells, was enriched in PI3K, hypoxia, and Epidermal growth factor receptor pathway, and enriched with Nuclear Receptor Subfamily 2 Group F Member 1 transcription factor activity. We observed an intense communication from the cancer cells to endothelial cells, mainly through the Vitronectin (VTN) to Kinase Insert Domain Receptor (KDR) pathway. A prognostic model targeting LIHC was constructed based on the disulfidoptosis-based DEGs, namely APLP2, PDIA6, YBX1, SPP1, whose accuracy was validated in multiple cohorts. Knockdown of APLP2 significantly increased the apoptosis and delayed cell cycle progression of LIHC cell line. ConclusionA prognostic model targeting LIHC was constructed based on the disulfidoptosis-related DEGs, which displayed high stability and accuracy in multiple cohorts. APLP2 played an active role in the carcinogenesis of LIHC by regulating the apoptosis and cell cycle.
引用
收藏
页码:612 / 625
页数:14
相关论文
共 29 条
  • [21] Cancer-associated fibroblasts up-regulate CCL2, CCL26, IL6 and LOXL2 genes related to promotion of cancer progression in hepatocellular carcinoma cells
    Lin, Zu-Yau
    Chuang, Yen-Hwang
    Chuang, Wan-Long
    BIOMEDICINE & PHARMACOTHERAPY, 2012, 66 (07) : 525 - 529
  • [22] ETV4 mediates the Wnt/β-catenin pathway through transcriptional activation of ANXA2 to promote hepatitis B virus-associated liver hepatocellular carcinoma progression
    Sun, Tianfeng
    Zhang, Jing
    JOURNAL OF BIOCHEMISTRY, 2021, 170 (05) : 663 - 673
  • [23] Functional Imaging of Liver Cancer (FLIC): Study protocol of a phase 2 trial of 18F-DCFPyL PET/CT imaging for patients with hepatocellular carcinoma
    Mena, Esther
    Shih, Joanna
    Chung, Joon-Yong
    Jones, Jennifer
    Rabiee, Atoosa
    Monge, Cecilia
    Turkbey, Baris
    Lindenberg, Liza
    Salerno, Kilian E.
    Kassin, Michael
    Wood, Brad
    Hernandez, Jonathan
    Maass-Moreno, Roberto
    Saboury, Babak
    Jakhete, Neha
    Molitoris, Jason K.
    Unger, Keith R.
    Choyke, Peter L.
    Escorcia, Freddy E.
    PLOS ONE, 2022, 17 (11):
  • [24] Cell proliferation index and the expression of p53 and Bcl-2 in tumorous and non-tumorous lesions of hepatocellular carcinoma and metastatic liver cancer
    Yoon, DS
    Cheong, JH
    Park, YN
    Kwon, SW
    Chi, HS
    Kim, BR
    YONSEI MEDICAL JOURNAL, 1998, 39 (05) : 424 - 429
  • [25] Cancer-associated fibroblast-induced M2-polarized macrophages promote hepatocellular carcinoma progression via the plasminogen activator inhibitor-1 pathway
    Chen, Shuhai
    Morine, Yuji
    Tokuda, Kazunori
    Yamada, Shinichiro
    Saito, Yu
    Nishi, Masaaki
    Ikemoto, Tetsuya
    Shimada, Mitsuo
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2021, 59 (02)
  • [26] The effect of AKR1C2 gene on hepatocarcinogenesis and its abnormal expression in hepatocellular carcinoma from Qidong, China, a liver cancer high risk area
    Lu, DD
    Zhang, XR
    Cao, XR
    PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2003, 30 (06) : 906 - 918
  • [27] RETRACTED: Circ-TCF4.85 silencing inhibits cancer progression through microRNA-486-5p-targeted inhibition of ABCF2 in hepatocellular carcinoma (Retracted Article)
    Gao, Jun
    Dai, Chao
    Yu, Xin
    Yin, Xiang-Bao
    Zhou, Fan
    MOLECULAR ONCOLOGY, 2020, 14 (02) : 447 - 461
  • [28] Sphingosine 1-phosphate receptor 2 promotes the onset and progression of non-alcoholic fatty liver disease-related hepatocellular carcinoma through the PI3K/AKT/mTOR pathway
    Wang, Ganggang
    Zhang, Xin
    Zhou, Zhijie
    Song, Chao
    Jin, Wenzhi
    Zhang, Hao
    Wu, Weixin
    Yi, Yong
    Cui, Hengguan
    Zhang, Ping
    Liu, Xinyu
    Xu, Weiqiang
    Shen, Xiaowei
    Shen, Weixing
    Wang, Xiaoliang
    DISCOVER ONCOLOGY, 2023, 14 (01)
  • [29] RETRACTED: Long Noncoding RNA OIP5-AS1 Promotes the Progression of Liver Hepatocellular Carcinoma via Regulating the hsa-miR-26a-3p/EPHA2 Axis (Retracted article. See vol. 30, pg. 324, 2022)
    Ma, Yu-Shui
    Chu, Kai-Jian
    Ling, Chang-Chun
    Wu, Ting-Miao
    Zhu, Xu-Chao
    Liu, Ji-Bin
    Yu, Fei
    Li, Zhi-Zhen
    Wang, Jing-Han
    Gao, Qing-Xiang
    Yi, Bin
    Wang, Hui-Min
    Gu, Li-Peng
    Li, Liu
    Tian, Lin-Lin
    Shi, Yi
    Jiang, Xiao-Qing
    Fu, Da
    Zhang, Xiong-Wen
    MOLECULAR THERAPY-NUCLEIC ACIDS, 2020, 21 : 229 - 241